MYH9 and neoplasm: Among the Bmal1 interactors, we chose to focus on Myh9 (non-muscle myosin IIA) in depth, because it has been implicated in melanoma tumorigenesis and drug resistance39,40, and thought to be a tumor suppressor in several tumor models41–44.